📖 Read November's eNews here
✅ Tony Jones, CEO, One Nucleus - Partnering, Policies and Parties
✅ Genesis Conference App Now Open! Start Your Networking Here...
✅ New Government Delivers Optimism and Concern for the Region’s Life Sciences by Tony Jones
✅ CRISPR – A Twist in the Tale in the Ongoing Patent Battle in Europe, by Appleyard Lees IP LLP
Company Description:
PharmaVentures is a premier transaction advisory firm based in the London Area, United Kingdom, specializing in partnering, M&A deals, and strategic alliances for over 30 years. With expertise in licensing, mergers, acquisitions, and divestments, PharmaVentures provides comprehensive support for companies worldwide. The company is known for its deep insight into deal structures and successful partnering strategies.
At One Nucleus, international connectivity is more than just a concept; it is at the core of what our members do and hence why we seek to complement that connectivity in how we support members. Whilst much of what One Nucleus delivers is done within the greater Cambridge-London region, our connectivity extends far beyond the UK.
By Tony Jones, CEO, One Nucleus
Recent weeks have been filled with varying degrees of anticipation and apprehension with regards to what UK government would start crystallising from grand election campaign gestures to actual measures and policies. After what felt like a long run of warnings of doom to the finally delivered ‘Invest 2025: the UK’s modern industrial strategy’ and ‘Autumn Budget 2024’.
By Alicia Gailliez, Business Development Manager, One Nucleus
Amsterdam, the Netherlands and Stevenage, UK – 4 November 2024 - Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment of Dr. Lara Boyd as Chief Business Officer.
Are you a life science SME ready to stay ahead in the rapidly evolving skills landscape? Join industry leaders, experts, and like-minded innovators for this exclusive webinar designed to equip you with insights and practical strategies around talent development.
Agenda Highlights include:
• First development candidate selected, NRG5051, with potential to treat Parkinson’s and Amyotrophic Lateral Sclerosis (ALS) (also known as Motor Neuron Disease, MND) and other neurodegenerative diseases
• NRG5051 prevents mitochondrial dysfunction via inhibition of the mitochondrial permeability transition pore (mPTP) through a novel protein target
• Inhibition of the mPTP in the brain prevents neuronal cell death and reduces neuroinflammation in animals
• $5M grant from The Michael J. Fox Foundation (MJFF) to advance NRG5051 into the clinic
For researchers looking to optimize protocols for cell culture and differentiation of ES/iPS cells - AMSBIO has introduced the iMatrix Palette. This new kit containing all variants of their iMatrix recombinant laminin E8 fragment isoforms** saving researchers time, cost, and improving reproducibility.
London, October 28, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for ArcticZymes Technologies ASA (OSE: AZT) and is pleased to announce the placement of Dr. Frank Mathias as Chair of the Board.